Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 923-934

  Lugade, Amit A ^a   Bharali, Dhruba J ^b   Pradhan, Vandana ^a,c   Elkin, Galina ^a   Mousa, Shaker A ^b   Thanavala, Yasmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c National Institute of Immunohaemotology   (India)

Author keywords

Adjuvant free; Anti HBs; HBsAg; Nanoparticle; Vaccine

Indexed keywords

ADJUVANT-FREE; ANTI-HBS; ANTIBODY RESPONSE; CHITOSAN NANOPARTICLES; DENDRITIC CELLS; HBSAG; HEPATITIS B SURFACE ANTIGEN; VACCINE DELIVERY SYSTEM;

ANTIBODIES; ANTIGENS; CHITOSAN; IMMUNIZATION; MAMMALS; VACCINES;

NANOPARTICLES;

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B SURFACE ANTIGEN NANOPARTICLE VACCINE; HEPATITIS B VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENCAPSULATION; ENDOCYTOSIS; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; INTERFERON PRODUCTION; LOW DRUG DOSE; MOUSE; NONHUMAN; PHENOTYPE; SINGLE DRUG DOSE; T LYMPHOCYTE;

MURINAE; MUS;

ADJUVANT-FREE; ANTI-HBS; HBSAG; NANOPARTICLE; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL DIFFERENTIATION; CHITOSAN; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY; IMMUNIZATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; NANOPARTICLES; PHENOTYPE;

EID: 84884279628     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.03.008     Document Type: Article

References (50)

1. Alper C.A. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet 1995, 12:171-181.
2. Kniskern P.J., Miller W.J. Hepatitis B vaccines: blueprints for vaccines of the future. Biotechnology 1992, 20:177-204.
3. Vogel F.R. Adjuvants in perspective. Dev Biol Stand 1998, 92:241-248.
4. Gherardi R.K., Coquet M., Cherin P., Belec L., Moretto P., Dreyfus P.A., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
5. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
6. Kool M., Fierens K., Lambrecht B.N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61:927-934.
7. Singla A.K., Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 2001, 53:1047-1067.
8. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998, 15:1326-1331.
9. Mhurchu C.N., Dunshea-Mooij C., Bennett D., Rodgers A. Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obes Rev 2005, 6:35-42.
10. Wedmore I., McManus J.G., Pusateri A.E., Holcomb J.B. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 2006, 60:655-658.
11. Muzzarelli R.A. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 2010, 8:292-312.
12. Neimert-Andersson T., Hallgren A.C., Andersson M., Langeback J., Zettergren L., Nilsen-Nygaard J., et al. Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine 2011, 29:8965-8973.
13. Wen Z.S., Xu Y.L., Zou X.T., Xu Z.R. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs 2011, 9:1038-1055.
14. Ghendon Y., Markushin S., Akopova I., Koptiaeva I., Krivtsov G. Chitosan as an adjuvant for poliovaccine. J Med Virol 2011, 83:847-852.
15. Aguado M.T. Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 1993, 11:596-597.
16. Cleland J.L. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 1999, 17:25-29.
17. Einmahl S., Behar-Cohen F., Tabatabay C., Savoldelli M., D'Hermies F., Chauvaud D., et al. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application. J Biomed Mater Res 2000, 50:566-573.
18. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
19. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003, 21:1478-1485.
20. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002, 13:1415-1425.
21. Bharali D.J., Pradhan V., Elkin G., Qi W., Hutson A., Mousa S.A., et al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine 2008, 4:311-317.
22. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109:1080-1085.
23. Bharali D.J., Mousa S.A., Thanavala Y. Micro- and nanoparticle-based vaccines for hepatitis B. Adv Exp Med Biol 2007, 601:415-421.
24. Jiang W., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005, 57:391-410.
25. O'Hagan D.T., Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003, 2:269-283.
26. Pyo H.M., Masic A., Woldeab N., Embury-Hyatt C., Lin L., Shin Y.K., et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine 2012, 30:1297-1304.
27. Ruiss R., Jochum S., Wanner G., Reisbach G., Hammerschmidt W., Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. J Virol 2011, 85:13105-13113.
28. Chang M.O., Suzuki T., Suzuki H., Takaku H. HIV-1 Gag-virus-like particles induce natural killer cell immune responses via activation and maturation of dendritic cells. J Innate Immun 2012, 4:187-200.
29. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vacc 2008, 4:5-12.
30. Lutsiak M.E., Robinson D.R., Coester C., Kwon G.S., Samuel J. Analysis of poly(D, L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002, 19:1480-1487.
31. Zhao Q., Towne V., Brown M., Wang Y., Abraham D., Oswald C.B., et al. In-depth process understanding of RECOMBIVAX HB(R) maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011, 29:7936-7941.
32. Dane D.S., Cameron C.H., Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1:695-698.
33. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298:347-350.
34. Huang Z., Elkin G., Maloney B.J., Beuhner N., Arntzen C.J., Thanavala Y., et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005, 23:1851-1858.
35. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25:2085-2094.
36. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine 2007, 25:8673-8686.
37. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293:2108-2111.
38. Schneider P., Mackay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
39. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
40. Bessa J., Kopf M., Bachmann M.F. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 2010, 184:4615-4619.
41. Hu H., Wu X., Jin W., Chang M., Cheng X., Sun S.C. Noncanonical NF-kappaB regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development. Proc Natl Acad Sci USA 2011, 108:12827-12832.
42. Mori A., Oleszycka E., Sharp F.A., Coleman M., Ozasa Y., Singh M., et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol 2012, 42:2709-2719.
43. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999, 163:6448-6454.
44. Kool M., Soullie T. van NM, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
45. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
46. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6:797-808.
47. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006, 24:S2-S9.
48. Carcaboso A.M., Hernandez R.M., Igartua M., Rosas J.E., Patarroyo M.E., Pedraz J.L. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004, 22:1423-1432.
49. Tabata Y., Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 1988, 22:837-858.
50. Mueller R.H. Colloidal carriers for controlled drug delivery and targeting: modification, characterization, and in vivo distribution 1991, CRC Press, Boston, p. 1-379. 1st ed.